{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:56:19Z","timestamp":1780077379648,"version":"3.54.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Individuals with a prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection have a moderate to high degree of protection against reinfection, though seemingly less so when the Omicron variant of SARS-CoV-2 started to circulate. The aim of this study was to evaluate the vaccine effectiveness (VE) against SARS-CoV-2 reinfection, Coronavirus Disease 2019 (COVID-19)-related hospitalization, and COVID-19-related death, in individuals with prior SARS-CoV-2 infection, and to assess the effect of time since vaccination during periods with different dominant SARS-CoV-2 variants.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>This study used a nationwide cohort design including all individuals with a confirmed SARS-CoV-2 infection, who were alive, and residing in Denmark between 1 January 2020 and 31 January 2022. Using Danish nationwide registries, we obtained information on SARS-CoV-2 infections, COVID-19 vaccination, age, sex, comorbidity, staying at hospital, and country of origin. The study population included were individuals with prior SARS-CoV-2 infection. Estimates of VE against SARS-CoV-2 reinfection with 95% confidence intervals (CIs) were calculated using a Poisson regression model and adjusted for age, sex, country of origin, comorbidity, staying at hospital, calendar time, and test incidence using a Cox regression model. The VE estimates were calculated separately for three periods with different dominant SARS-CoV-2 variants (Alpha (B.1.1.7), Delta (B.1.617.2), or Omicron (B.1.1.529)) and by time since vaccination using unvaccinated as the reference. In total, 148,527 person-years and 44,192 SARS-CoV-2 infections were included for the analysis regarding reinfections. The study population comprised of 209,814 individuals infected before or during the Alpha period, 292,978 before or during the Delta period, and 245,530 before or during the Omicron period. Of these, 40,281 individuals had completed their primary vaccination series during the Alpha period (19.2%), 190,026 during the Delta period (64.9%), and 158,563 during the Omicron period (64.6%). VE against reinfection following any COVID-19 vaccine type administered in Denmark, peaked at 71% (95% CI: -Inf to 100%) at 104 days or more after vaccination during the Alpha period, 94% (95% CI: 92% to 96%) 14 to 43 days after vaccination during the Delta period, and 60% (95% CI: 58% to 62%) 14 to 43 days after vaccination during the Omicron period. Waning immunity following vaccination was observed and was most pronounced during the Omicron period. Due to too few events, it was not possible to estimate VE for hospitalization and death. Study limitations include potentially undetected reinfections, differences in health-seeking behavior, or risk behavior between the compared groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study shows that in previously infected individuals, completing a primary vaccination series was associated with a significant protection against SARS-CoV-2 reinfection compared with no vaccination. Even though vaccination seems to protect to a lesser degree against reinfection with the Omicron variant, these findings are of public health relevance as they show that previously infected individuals still benefit from COVID-19 vaccination in all three variant periods.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004037","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T18:22:10Z","timestamp":1669141330000},"page":"e1004037","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":45,"title":["Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8847-9850","authenticated-orcid":true,"given":"Katrine Finderup","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Rask","family":"Moustsen-Helms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9187-7822","authenticated-orcid":true,"given":"Astrid Blicher","family":"Schelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0039","authenticated-orcid":true,"given":"Mie Agermose","family":"Gram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-0864","authenticated-orcid":true,"given":"Hanne-Dorthe","family":"Emborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5949-0097","authenticated-orcid":true,"given":"Christian Holm","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Asger","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Meaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Wohlfahrt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle","family":"Valentiner-Branth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"pmed.1004037.ref001","article-title":"The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study","author":"S Gazit","year":"2022","journal-title":"Ann Intern Med"},{"key":"pmed.1004037.ref002","first-page":"NEJMoa2119497","article-title":"Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19","author":"A Hammerman","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004037.ref003","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.15585\/mmwr.mm7032e1","article-title":"Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination\u2014Kentucky, May\u2013June 2021","volume":"70","author":"AM Cavanaugh","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"pmed.1004037.ref004","first-page":"ciac262","article-title":"SARS-CoV-2 Naturally Acquired Immunity vs. Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: a Retrospective Cohort Study","author":"S Gazit","year":"2022","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"pmed.1004037.ref005","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2","volume":"386","author":"Y Goldberg","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004037.ref006","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study","volume":"397","author":"CH Hansen","year":"2021","journal-title":"Lancet"},{"key":"pmed.1004037.ref007","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1056\/NEJMc2200133","article-title":"Protection against the Omicron Variant from Previous SARS-CoV-2 Infection","volume":"386","author":"HN Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004037.ref008","doi-asserted-by":"crossref","first-page":"100452","DOI":"10.1016\/j.lanepe.2022.100452","article-title":"Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data","volume":"20","author":"D Michlmayr","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"pmed.1004037.ref009","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2147\/CLEP.S179083","article-title":"The Danish health care system and epidemiological research: from health care contacts to database records","volume":"11","author":"M Schmidt","year":"2019","journal-title":"Clin Epidemiol."},{"key":"pmed.1004037.ref010","article-title":"Vaccination calendar","author":"Danish Health Authority","year":"2021","journal-title":"Danish Health Authority [Internet]"},{"key":"pmed.1004037.ref011","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"M Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"pmed.1004037.ref012","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apm.13140","article-title":"Electronic reporting of diagnostic laboratory test results from all healthcare sectors is a cornerstone of national preparedness and control of COVID-19 in Denmark","volume":"129","author":"K Sch\u00f8nning","year":"2021","journal-title":"APMIS"},{"key":"pmed.1004037.ref013","first-page":"7","author":"Sundheds- og \u00c6ldreministeriet","year":"2018","journal-title":"Danish Act no. 1615 on access to and registration of pharmaceutical and vaccination information of 18 December 2018 [Bekendtg\u00f8relse om adgang til og registrering m.v. af l\u00e6gemiddel- og vaccinationsoplysninger]"},{"key":"pmed.1004037.ref014","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"M Schmidt","year":"2015","journal-title":"Clin Epidemiol."},{"key":"pmed.1004037.ref015","doi-asserted-by":"crossref","first-page":"e1003874","DOI":"10.1371\/journal.pmed.1003874","article-title":"Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study","volume":"18","author":"MA Gram","year":"2021","journal-title":"PLoS Med."},{"key":"pmed.1004037.ref016","doi-asserted-by":"crossref","first-page":"100954","DOI":"10.1016\/j.eclinm.2021.100954","article-title":"Validation of a rapid antigen test as a screening tool for SARS-CoV-2 infection in asymptomatic populations. Sensitivity, specificity and predictive values","volume":"37","author":"A Fernandez-Montero","year":"2021","journal-title":"EClinicalMedicine"},{"key":"pmed.1004037.ref017","first-page":"2022.04.20.22274061","article-title":"Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study","author":"MA Gram","year":"2022","journal-title":"MedRxiv Prepr"},{"key":"pmed.1004037.ref018","unstructured":"European Medicines Agency. EMEA\/H\/C\/005791\u2014IB\/0072\u2014Spikevax (previously COVID-19 Vaccine Moderna): EPAR\u2014Product information [Internet]. [cited 2022 Apr 26]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf."},{"key":"pmed.1004037.ref019","unstructured":"European Medicines Agency. EMEA\/H\/C\/005737\u2014II\/0048\/G -Jcovden (previously COVID-19 Vaccine Janssen): EPAR\u2014Product information [Internet]. [cited 2022 Aug 1]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_en.pdf."},{"key":"pmed.1004037.ref020","unstructured":"European Medicines Agency. EMEA\/H\/C\/005675\u2014II\/0074\u2014Vaxzevria (previously COVID-19 Vaccine AstraZeneca): EPAR\u2014Product information [Internet]. [cited 2022 Aug 1]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf."},{"key":"pmed.1004037.ref021","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"18","author":"E von Elm","year":"2007","journal-title":"Epidemiology"},{"key":"pmed.1004037.ref022","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s43587-021-00114-7","article-title":"SARS-CoV-2, COVID-19 and the aging immune system","volume":"1","author":"JM Bartleson","year":"2021","journal-title":"Nat Aging."},{"key":"pmed.1004037.ref023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"DA Collier","year":"2021","journal-title":"Nature"},{"key":"pmed.1004037.ref024","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/cid\/ciab381","article-title":"Age-dependent Immune Response to the Biontech\/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination","volume":"73","author":"L M\u00fcller","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pmed.1004037.ref025","first-page":"S1473309922001438","article-title":"Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden","author":"P Nordstr\u00f6m","year":"2022","journal-title":"Lancet Infect Dis."},{"key":"pmed.1004037.ref026","first-page":"NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection","author":"V Hall","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004037.ref027","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections","volume":"387","author":"HN Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004037.ref028","doi-asserted-by":"crossref","first-page":"549","DOI":"10.15585\/mmwr.mm7115e2","article-title":"Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19\u2013Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection\u2014United States, June 2021\u2013February 2022","volume":"71","author":"ID Plumb","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"pmed.1004037.ref029","doi-asserted-by":"crossref","first-page":"n1127","DOI":"10.1136\/bmj.n1127","article-title":"Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows","volume":"373","author":"E. Mahase","year":"2021","journal-title":"BMJ"},{"key":"pmed.1004037.ref030","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jamda.2020.05.045","article-title":"The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects","volume":"21","author":"C Bonanad","year":"2020","journal-title":"J Am Med Dir Assoc."},{"key":"pmed.1004037.ref031","article-title":"Coronavirus Pandemic (COVID-19)","author":"H Ritchie","year":"2020","journal-title":"Our World Data"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T18:22:28Z","timestamp":1669141348000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004037"}},"subtitle":[],"editor":[{"given":"James G.","family":"Beeson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004037","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}